Retraction: Identifying the inhibitory mechanism of apigenin on the insulin ligand–receptor binding

Yong Yang


I, the named author, hereby wholly retract this MedChemComm article due to extensive text and data overlap with a previous publication that I co-authored.1

Fig. 1b–d, 2b–d, 3a and 3b in this MedChemComm paper were copied from ref. 1 and do not represent results from experiments with apigenin.

This retraction supersedes the information provided in the Expression of Concern related to this article.

Signed: Yong Yang, 22nd June 2016.

Retraction endorsed by Richard Kelly, Executive Editor, MedChemComm.


Institute of Metabolic Disease Research and Drug Development, China Medical University, Shenyang, Liaoning 110001, People’s Republic of China.
E-mail: yyang@mail.cmu.edu.cn; Tel: +86 18900911994